Searched for
BEVACIZUMAB BIOSIMILAR
Aurobindo Pharma arm CuraTeQ gets Health Canada nod for biosimilarAurobindo Pharma announced a significant development today. Its subsidiary, CuraTeQ Biologics, has received a compliance notice from Health...- Biocon plans $150-million capex in two yearsBiocon plans a $150 million capital expenditure, allocating $100 million to biologics, primarily enhancing Malaysian capacities, and $50 mi...
- Biocon shares rally nearly 6% after unit receives USFDA nod for cancer drugBiocon's shares surged following USFDA approval for Jobevne, a biosimilar to Avastin, used in treating various cancers. This marks Biocon's...
- Biocon Biologics gets EMA nod to produce biosimilar Bevacizumab at Bengaluru plantBiocon Biologics received EMA approval to manufacture biosimilar Bevacizumab in Bengaluru, providing additional capacity to address patient...
- Biocon Biologics focusing on market share gains of biosimilars in key marketsBiocon Biologics is focused on improving cash flows and increasing market shares of its biosimilar products, particularly in the US and Eur...
- Biocon Biologics completes integration of Viatris' Europe biosimilar businessBiocon Biologics on Thursday said it has completed the integration of the acquired biosimilar business from Viatris Inc in 31 European coun...
- USFDA issues CRL for Bevacizumab license application moved by Viatris: Biocon"The USFDA has issued a CRL for the Biologics License Application (BLA) for Bevacizumab filed by our partner Viatris (Mylan)," a company sp...
- Biocon climbs 4% as pharma giant’s arm launches cancer treatment product AbevmyBiocon’s share price climbed to a high of Rs 334.70 as against Rs 322.95 at previous close on the BSE.Abevmy is a recombinant humanized mon...
- Biocon Biologics, Viatris receive approval for cancer drugAbevmy is approved for treatment in metastatic colorectal carcinoma, metastatic breast cancer, non small-cell lung carcinoma, glioblastoma,...
- Biocon Biologics, Viatris Inc. get CHMP nod for Abevmy, a biosimilar to AvastinAbevmy is abiosimilar to Roche's Avastin, prescribed for all indications including metastatic colorectal carcinoma, metastatic breast cance...
- USFDA informs Biocon Biologics, Mylan of deferred action on Avastin biosimilar license application"To complete the application, the agency noted that an inspection of the manufacturing facility is required as a part of the standard revie...
- US FDA accepts Biocon's cancer drug application for reviewBiocon and Mylan’s proposed biosimilar bevacizumab, a cancer drug, is expected to be the third biosimilar from the partnered portfolio for ...
- Desi pharma companies top in biosimilars globallyBiosimilars are approved versions of biopharmaceuticals — complex medicines manufactured using live organisms, as against conventional drug...
- Biocon teams up with Swiss drugmaker Sandoz for next gen biosimilarUnder the terms of the agreement, both companies will share responsibility for end to end development, manufacturing and global regulatory ...
- Biocon shares gains on cancer drug launchA biosimilar is a near copy of an original complex biologic drug.
- Biocon introduces oncologic biosimilar KRABEVA in IndiaThe biosimilar product will be used for the treatment of patients with metastatic colorectal cancer and other types of lung, kidney, cervic...
- Intas launches biosimilar Bevacizumab with aggressive pricingBiosimilar drugs are the follow on versions of biologic drugs which are composed of sugars, proteins, nucleic acids or complex combinations...
- Reliance Lifesciences launches world's first biosimilar used to treat advanced cancersIn 2014, Reliance had entered into a similar arrangement with Torrent Pharma to sell copies of three drugs -- rituximab, adalimumab and cet...
- Delhi High Court asks Roche to explain lawsuit over Avastin copyRoche, which invented the drug and markets it under the blockbuster brand ‘Avastin’, has argued that Hetero’s drug is not a biosimilar to b...
- Roche’s reputation at stake if Avastin biosimilar approved without trial: Kapil SibalThe judge asked the company to submit a compilation of judgments highlighting the protection given to drug innovators to support its call.
Load More
